Journal
ANTIOXIDANTS & REDOX SIGNALING
Volume 33, Issue 6, Pages 455-479Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2020.8032
Keywords
NADPH oxidases; pharmacology; tissue repair and remodeling; myofibroblasts; aging; clinical
Funding
- NIH [P01 HL114470, R01 AG046210, R01HL139617]
- U.S. Department of Veterans Affairs Merit Award [I01BX003056]
Ask authors/readers for more resources
Recent Advances: There is emerging evidence to support a combination of genetic, environmental, and age-related risk factors contributing to susceptibility and/or progression of fibrosis in different organ systems. A core pathway in fibrogenesis involving these organs is the induction and activation of nicotinamide adenine dinucleotide phosphate oxidase (NOX) family enzymes. Critical Issues: We explore current pharmaceutical approaches to targeting NOX enzymes, including repurposing of currently U.S. Food and Drug Administration (FDA)-approved drugs. Specific inhibitors of various NOX homologs will aid establishing roles of NOXs in the various organ fibroses and potential efficacy to impede/halt disease progression. Future Directions: The discovery of novel and highly specific NOX inhibitors will provide opportunities to develop NOX inhibitors for treatment of fibrotic pathologies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available